General
Preferred name
inositol nicotinate
Synonyms
INOSITOL NIACINATE ()
Hexanicotol ()
Myo-Inositol hexanicotinate ()
Mesotal ()
Dilexpal ()
Inositol hexanicotinate ()
Hexopal ()
Hexanicit ()
Linodil ()
Nicotinate d'inositol ()
WIN-9154 ()
NSC-49506 ()
Palohex ()
WIN 9154 ()
Hamovannid ()
Esantene ()
Mesonex ()
Nicotinato de inositol ()
Dilcit ()
P&D ID
PD072056
CAS
6556-11-2
Tags
available
drug
Approved by
FDA
Drug Status
approved
investigational
withdrawn
Max Phase
2.0
Drug indication
Cardiovascular disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 42
DESCRIPTION Inositol nicotinate (Mesotal) has the effect of lowering cholesterol and expanding peripheral blood vessels for hypercholesterolemia and atherosclerosis. (TargetMol Bioactive Compound Library)
Compound Sets
9
ChEMBL Drugs
CHEMBL1094982
Drug Repurposing Hub
DrugBank
DB08949
DrugBank Approved Drugs
DB08949
DrugCentral
1445
DrugCentral Approved Drugs
1445
MedChem Express Bioactive Compound Library
HY-122365
ReFrame library
TargetMol Bioactive Compound Library
T4509
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
810.19
Hydrogen Bond Acceptors
18
Hydrogen Bond Donors
0
Rotatable Bonds
12
Ring Count
7
Aromatic Ring Count
6
cLogP
3.72
TPSA
235.14
Fraction CSP3
0.14
Chiral centers
0.0
Largest ring
6.0
QED
0.13
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)
Disease Area
dermatology, cardiology, rheumatology, neurology/psychiatry
Source data